Postes actifs de Ashleigh Barreto
Sociétés | Poste | Début | Fin |
---|---|---|---|
VIRACTA THERAPEUTICS, INC. | Investor Relations Contact | 01/10/2021 | - |
Public Communications Contact | 01/10/2021 | - |
Historique de carrière de Ashleigh Barreto
Anciens postes connus de Ashleigh Barreto
Sociétés | Poste | Début | Fin |
---|---|---|---|
ADAMAS PHARMACEUTICALS, INC. | Investor Relations Contact | - | 01/12/2018 |
Public Communications Contact | - | 01/12/2018 | |
XOMA CORPORATION | Investor Relations Contact | - | - |
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Investor Relations Contact | 3 |
Public Communications Contact | 2 |
Sectorielle
Health Technology | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
XOMA CORPORATION | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
- Bourse
- Insiders
- Ashleigh Barreto
- Expérience